Overview

Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)

Status:
Unknown status

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

This will be a randomized, double-blind, placebo-controlled, multi-center, multi-national, escalating dose, pilot study comparing two doses of THR-18 to placebo when administered to patients suffering acute ischemic stroke and treated with Tissue Plasminogen Activator (tPA). The study hypothesis is that THR-18 will be safe and well tolerated in subjects suffering acute ischemic stroke and treated with Thrombolysis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Thrombotech Ltd.

Treatments:

Plasminogen
Tissue Plasminogen Activator